Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents

Roger J. M. Bruggemann*, Jan-Willem C. Alffenaar, Nicole M. A. Blijlevens, Eliane M. Billaud, Jos G. W. Kosterink, Paul E. Verweij, David M. Burger

*Bijbehorende auteur voor dit werk

Onderzoeksoutputpeer review

278 Citaten (Scopus)


There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posaconazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.

Originele taal-2English
Pagina's (van-tot)1441-1458
Aantal pagina's18
TijdschriftClinical Infectious Diseases
Nummer van het tijdschrift10
StatusPublished - 15-mei-2009

Citeer dit